TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest update is out from RedHill Biopharma ( (RDHL) ).
On October 6, 2025, RedHill Biopharma announced a new licensing agreement for Talicia in the Middle East, potentially worth $1.8 million plus sales royalties. This deal includes $500,000 in guaranteed payments and aims to expand Talicia’s market presence in regions with high H. pylori prevalence, enhancing RedHill’s market positioning and addressing significant medical needs.
The most recent analyst rating on (RDHL) stock is a Hold with a $2.50 price target. To see the full list of analyst forecasts on RedHill Biopharma stock, see the RDHL Stock Forecast page.
Spark’s Take on RDHL Stock
According to Spark, TipRanks’ AI Analyst, RDHL is a Neutral.
The overall stock score of 52 reflects significant financial challenges faced by RedHill Biopharma, including negative equity and cash flow issues. While technical analysis shows positive short-term momentum, overbought conditions suggest caution. The lack of valuation data adds uncertainty, impacting the overall assessment.
To see Spark’s full report on RDHL stock, click here.
More about RedHill Biopharma
RedHill Biopharma Ltd. is a specialty biopharmaceutical company focused on developing and commercializing therapies for gastrointestinal diseases. Their primary product, Talicia, is an FDA-approved therapy for H. pylori infection, a significant risk factor for gastric cancer.
Average Trading Volume: 1,390,399
Technical Sentiment Signal: Sell
Current Market Cap: $6.33M
For a thorough assessment of RDHL stock, go to TipRanks’ Stock Analysis page.